Reich CG - Search Results

1

Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study.

Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J, Pratt N, Reich CG, Madigan D, You SC, Ryan PB, Hripcsak G. Chen R, et al. Among authors: reich cg. Hypertension. 2021 Sep;78(3):591-603. doi: 10.1161/HYPERTENSIONAHA.120.16667. Epub 2021 Jul 26. Hypertension. 2021. PMID: 34304580 Free PMC article.

2

Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership.

Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, Welebob E, Scarnecchia T, Woodcock J. Stang PE, et al. Ann Intern Med. 2010 Nov 2;153(9):600-6. doi: 10.7326/0003-4819-153-9-201011020-00010. Ann Intern Med. 2010. PMID: 21041580

3

Validation of a common data model for active safety surveillance research.

Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Overhage JM, et al. Among authors: reich cg. J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54-60. doi: 10.1136/amiajnl-2011-000376. Epub 2011 Oct 28. J Am Med Inform Assoc. 2012. PMID: 22037893 Free PMC article.

4

Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases.

Reich C, Ryan PB, Stang PE, Rocca M. Reich C, et al. J Biomed Inform. 2012 Aug;45(4):689-96. doi: 10.1016/j.jbi.2012.05.002. Epub 2012 Jun 7. J Biomed Inform. 2012. PMID: 22683994 Free article.

5

Managing data quality for a drug safety surveillance system.

Hartzema AG, Reich CG, Ryan PB, Stang PE, Madigan D, Welebob E, Overhage JM. Hartzema AG, et al. Among authors: reich cg. Drug Saf. 2013 Oct;36 Suppl 1:S49-58. doi: 10.1007/s40264-013-0098-7. Drug Saf. 2013. PMID: 24166223

6

A comparison of the empirical performance of methods for a risk identification system.

Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, Reich CG, Schuemie MJ, Madigan D. Ryan PB, et al. Among authors: reich cg. Drug Saf. 2013 Oct;36 Suppl 1:S143-58. doi: 10.1007/s40264-013-0108-9. Drug Saf. 2013. PMID: 24166231

7

Alternative outcome definitions and their effect on the performance of methods for observational outcome studies.

Reich CG, Ryan PB, Schuemie MJ. Reich CG, et al. Drug Saf. 2013 Oct;36 Suppl 1:S181-93. doi: 10.1007/s40264-013-0111-1. Drug Saf. 2013. PMID: 24166234

8

The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.

Reich CG, Ryan PB, Suchard MA. Reich CG, et al. Drug Saf. 2013 Oct;36 Suppl 1:S195-204. doi: 10.1007/s40264-013-0112-0. Drug Saf. 2013. PMID: 24166235

9

Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest.

Boyce RD, Ryan PB, Norén GN, Schuemie MJ, Reich C, Duke J, Tatonetti NP, Trifirò G, Harpaz R, Overhage JM, Hartzema AG, Khayter M, Voss EA, Lambert CG, Huser V, Dumontier M. Boyce RD, et al. Among authors: reich c. Drug Saf. 2014 Aug;37(8):557-67. doi: 10.1007/s40264-014-0189-0. Drug Saf. 2014. PMID: 24985530 Free PMC article.

10

Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model.

Matcho A, Ryan P, Fife D, Reich C. Matcho A, et al. Drug Saf. 2014 Nov;37(11):945-59. doi: 10.1007/s40264-014-0214-3. Drug Saf. 2014. PMID: 25187016 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

107 results

Search Page